132 related articles for article (PubMed ID: 23500606)
21. Albumin and Protein Oxidation are Predictors that Differentiate Relapsing-Remitting from Progressive Clinical Forms of Multiple Sclerosis.
Oliveira SR; Kallaur AP; Reiche EMV; Kaimen-Maciel DR; Panis C; Lozovoy MAB; Morimoto HK; Maes M; Dichi I; Simão ANC
Mol Neurobiol; 2017 May; 54(4):2961-2968. PubMed ID: 27026183
[TBL] [Abstract][Full Text] [Related]
22. IL17 and IFNgamma production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis.
Frisullo G; Nociti V; Iorio R; Patanella AK; Marti A; Caggiula M; Mirabella M; Tonali PA; Batocchi AP
Cytokine; 2008 Oct; 44(1):22-5. PubMed ID: 18793860
[TBL] [Abstract][Full Text] [Related]
23. Absence of cerebrospinal fluid oligoclonal bands is associated with delayed disability progression in relapsing-remitting MS patients treated with interferon-beta.
Annunziata P; Giorgio A; De Santi L; Zipoli V; Portaccio E; Amato MP; Clerici R; Scarpini E; Moscato G; Iudice A; Vacca G; Orefice G; Morra VB; Maimone D
J Neurol Sci; 2006 May; 244(1-2):97-102. PubMed ID: 16473370
[TBL] [Abstract][Full Text] [Related]
24. A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis.
Calabrese M; Rocca MA; Atzori M; Mattisi I; Favaretto A; Perini P; Gallo P; Filippi M
Ann Neurol; 2010 Mar; 67(3):376-83. PubMed ID: 20373349
[TBL] [Abstract][Full Text] [Related]
25. Degenerative and inflammatory markers in the cerebrospinal fluid of multiple sclerosis patients with relapsing-remitting course of disease and after clinical isolated syndrome.
Sladkova V; Mareš J; Lubenova B; Zapletalova J; Stejskal D; Hlustik P; Kanovsky P
Neurol Res; 2011 May; 33(4):415-20. PubMed ID: 21535941
[TBL] [Abstract][Full Text] [Related]
26. CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosis.
Tumani H; Lehmensiek V; Rau D; Guttmann I; Tauscher G; Mogel H; Palm C; Hirt V; Suessmuth SD; Sapunova-Meier I; Ludolph AC; Brettschneider J
Neurosci Lett; 2009 Mar; 452(2):214-7. PubMed ID: 19383442
[TBL] [Abstract][Full Text] [Related]
27. Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study.
Boster A; Hreha S; Berger JR; Bao F; Penmesta R; Tselis A; Endress C; Zak I; Perumal J; Caon C; Vazquez J; Tyler KL; Racke MK; Millis S; Khan O
Arch Neurol; 2009 May; 66(5):593-9. PubMed ID: 19433659
[TBL] [Abstract][Full Text] [Related]
28. Oxidative stress markers are increased since early stages of infection in syphilitic patients.
Hébert-Schuster M; Borderie D; Grange PA; Lemarechal H; Kavian-Tessler N; Batteux F; Dupin N
Arch Dermatol Res; 2012 Nov; 304(9):689-97. PubMed ID: 23011658
[TBL] [Abstract][Full Text] [Related]
29. Interleukin-12p40 in the spinal fluid as a biomarker for clinically isolated syndrome.
Orbach R; Gurevich M; Achiron A
Mult Scler; 2014 Jan; 20(1):35-42. PubMed ID: 23722323
[TBL] [Abstract][Full Text] [Related]
30. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis.
Teunissen CE; Iacobaeus E; Khademi M; Brundin L; Norgren N; Koel-Simmelink MJ; Schepens M; Bouwman F; Twaalfhoven HA; Blom HJ; Jakobs C; Dijkstra CD
Neurology; 2009 Apr; 72(15):1322-9. PubMed ID: 19365053
[TBL] [Abstract][Full Text] [Related]
31. Investigation of protein oxidation and lipid peroxidation in patients with rheumatoid arthritis.
Baskol G; Demir H; Baskol M; Kilic E; Ates F; Karakukcu C; Ustdal M
Cell Biochem Funct; 2006; 24(4):307-11. PubMed ID: 16142689
[TBL] [Abstract][Full Text] [Related]
32. Short-term brain atrophy changes in relapsing-remitting multiple sclerosis.
Zivadinov R; Bagnato F; Nasuelli D; Bastianello S; Bratina A; Locatelli L; Watts K; Finamore L; Grop A; Dwyer M; Catalan M; Clemenzi A; Millefiorini E; Bakshi R; Zorzon M
J Neurol Sci; 2004 Aug; 223(2):185-93. PubMed ID: 15337621
[TBL] [Abstract][Full Text] [Related]
33. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
34. Influence of apolipoprotein E epsilon4 genotype on brain tissue integrity in relapsing-remitting multiple sclerosis.
De Stefano N; Bartolozzi ML; Nacmias B; Zipoli V; Mortilla M; Guidi L; Siracusa G; Sorbi S; Federico A; Amato MP
Arch Neurol; 2004 Apr; 61(4):536-40. PubMed ID: 15096402
[TBL] [Abstract][Full Text] [Related]
35. Decreased concentration of Klotho in the cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis.
Emami Aleagha MS; Siroos B; Ahmadi M; Balood M; Palangi A; Haghighi AN; Harirchian MH
J Neuroimmunol; 2015 Apr; 281():5-8. PubMed ID: 25867461
[TBL] [Abstract][Full Text] [Related]
36. [Th17-mediated relapsing-remitting multiple sclerosis is nonresponsive to interferon-β1b].
Zhang X; Zhang Q; Shi X; Yin R; Zhang Z; Hou X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jul; 29(7):751-3. PubMed ID: 23837989
[TBL] [Abstract][Full Text] [Related]
37. Quantitative assessment of brain iron by R(2)* relaxometry in patients with clinically isolated syndrome and relapsing-remitting multiple sclerosis.
Khalil M; Enzinger C; Langkammer C; Tscherner M; Wallner-Blazek M; Jehna M; Ropele S; Fuchs S; Fazekas F
Mult Scler; 2009 Sep; 15(9):1048-54. PubMed ID: 19556316
[TBL] [Abstract][Full Text] [Related]
38. [Natalizumab and reduction of carbonylated proteins in patients with multiple sclerosis].
Tasset I; Aguera E; Gascon F; Giraldo AI; Salcedo M; Cruz AH; Sanchez F; Tunez I
Rev Neurol; 2012 Apr; 54(8):449-52. PubMed ID: 22492096
[TBL] [Abstract][Full Text] [Related]
39. Assessment of nitric oxide, advanced oxidation protein products, malondialdehyde, and thiol levels in patients with restless legs syndrome.
Baskol G; Korkmaz S; Erdem F; Caniklioglu A; Kocyigit M; Aksu M
Sleep Med; 2012 Apr; 13(4):414-8. PubMed ID: 22469072
[TBL] [Abstract][Full Text] [Related]
40. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis.
Stein MS; Liu Y; Gray OM; Baker JE; Kolbe SC; Ditchfield MR; Egan GF; Mitchell PJ; Harrison LC; Butzkueven H; Kilpatrick TJ
Neurology; 2011 Oct; 77(17):1611-8. PubMed ID: 22025459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
